<DOC>
	<DOC>NCT00223977</DOC>
	<brief_summary>This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.</brief_summary>
	<brief_title>2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male or female, at least 18 years of age. Received maintenance peritoneal dialysis therapy for at least 4 weeks. Was expected to remain on peritoneal dialysis therapy for duration of study. Had predetermined low hemoglobin and transferrin saturation (TSAT) levels. Signed patient informed consent. Had a predetermined serum levels of Ferritin and TSAT Pregnant or lactating. Had a serious concomitant medical disorder incompatible with participation in the study. Had a known hypersensitivity to Ferrlecit or any of its components. Unable to cooperate or comply with the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Anemia.</keyword>
</DOC>